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Pmino-Terminal Pro-Brain Natriuretic Peptide,
enal Function, and Outcomes in Acute Heart Failure
edefining the Cardiorenal Interaction?
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aastricht, the Netherlands; Boston, Massachusetts; Christchurch, New Zealand; and Barcelona, Spain
OBJECTIVES We sought to study the individual and integrative role of amino-terminal pro-brain
natriuretic peptide (NT-proBNP) and parameters of renal function for prognosis in heart
failure.
BACKGROUND Amino-terminal pro-BNP and renal impairment both predict death in patients with heart
failure. Worsening of renal function in heart failure even defines the “cardiorenal syndrome.”
METHODS Seven hundred twenty subjects presenting with acute heart failure from 4 university-affiliated
medical centers were dichotomized according to NT-proBNP concentration and baseline
glomerular filtration rate. In addition, patients were divided according to changes in renal
function. The primary end point was 60-day mortality.
RESULTS The combination of a glomerular filtration rate (GFR) 60 ml/min/1.73 m2 with an
NT-proBNP 4,647 pg/ml was the best predictor of 60-day mortality (odds ratio 3.46; 95%
confidence interval 2.13 to 5.63). Among subjects with an NT-proBNP above the median,
those with a GFR 60 ml/min/1.73 m2 or a creatinine rise 0.3 mg/dl had the worst
prognosis, whereas in subjects with a NT-proBNP below the median, prognosis was not
influenced by either impaired renal function at presentation or the development of renal
impairment during admission.
CONCLUSIONS The combination of NT-proBNP with measures of renal function better predicts short-term
outcome in acute heart failure than either parameter alone. Among heart failure patients, the
objective parameter of NT-proBNP seems more useful to delineate the “cardiorenal
syndrome” than the previous criteria of a clinical diagnosis of heart failure. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.056Cardiol 2006;48:1621–7) © 2006 by the American College of Cardiology Foundation
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tn the setting of heart failure (HF), impaired renal function
s common and strongly predicts adverse outcomes (1–3).
his intersection of cardiac and renal insufficiency has been
eferred to as the “cardiorenal syndrome,” particularly when
cute HF is paralleled by a drop in renal function (4,5). The
elationship between cardiac and renal insufficiency may
eflect common risk factors for both morbidities (such as
iabetes, hypertension, and atherosclerosis) or impaired
enal blood flow related to HF with resultant progressive
eterioration of renal function. Whatever the mechanism,
enal insufficiency in a patient with HF is an established
arker of risk, which to date has been considered indepen-
ent of other risk factors in HF, such as advanced age or left
entricular function.
Both B-type, or brain, natriuretic peptide (BNP) and its
leavage equivalent, amino-terminal pro-BNP (NT-
roBNP) are rapidly released from cardiomyocytes after
tretch (6) and are established diagnostic and prognostic
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ccepted June 5, 2006.arkers in chronic as well as acute HF (7–9). Notably, a
ignificant inverse relationship exists between renal function
nd these cardiac peptides, with higher levels of both BNP
nd NT-proBNP observed in patients with impairment in
enal function, either with or without clinical HF (10–12).
espite earlier suggestions that such elevations in BNP and
T-proBNP were merely reflective of passive accumulation
ue to reduced clearance in the setting of renal insufficiency
nd thus impairing their use in HF patients with renal
mpairment (13), more recent data suggest that concentra-
ions of natriuretic peptides in patients with renal insuffi-
iency may parallel the presence and severity of cardiac
bnormalities in such patients and may offer powerful
rognostic information as well (12,14). Thus, the relation-
hip between NT-proBNP, structural heart disease, and
enal function remains incompletely understood. Accord-
ngly, in an effort to better understand the interplay between
easures of cardiac and renal insufficiencies, we analyzed
he relationship between NT-proBNP concentrations, renal
unction, and outcomes in subjects with acute HF.
ETHODS
atients. The ICON (International Collaborative on NT-
roBNP) study has been previously published (15). Briefly,
he study population consists of patients from 3 previously
eported prospective clinical studies of natriuretic peptide
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NT-proBNP, Renal Function, and Outcome in HF October 17, 2006:1621–7esting for the evaluation of dyspneic subjects, from
hristchurch, New Zealand (16), Barcelona, Spain (17),
nd Boston, Massachusetts (8), combined with a registry of
onsecutively admitted HF patients at the University Hospital
f Maastricht, the Netherlands. Of the total of 1,256 subjects,
20 subjects had acute HF and the remainder had dyspnea
ithout acute HF. In the Maastricht, Boston, and Barce-
ona studies, the final diagnosis for each patient was as-
igned by a panel of experienced clincial physicians using all
vailable clinical data from presentation to 76-day follow-up
8,15,17). In the Christchurch study, the criteria from the
uropean Society of Cardiology were used to diagnosis or
xclude HF (16,18). However, all data sources had compat-
ble inclusion/exclusion criteria and obtained similar clinical
nformation, including standard demographics, medical his-
ory, drug therapy, presenting symptoms and signs, physical
xamination, results of laboratory testing, chest X-ray in-
ormation, and electrocardiography results.
aboratory results. In all patients, blood samples were
rawn at the moment of presentation, before any therapy
as given. From this baseline creatinine, dynamic changes
n creatinine concentration were evaluated.
Amino-terminal pro-BNP levels were determined by an
mmunoelectrochemiluminisence method (Elecsys; Roche
iagnostics, Basel, Switzerland) and expressed in pg/ml.
For conversion, 1.0 pg/ml equals 1.0 ng/l. Creatinine
evels were determined by standard laboratory testing at
ach individual hospital. Glomerular filtration rate (GFR)
as calculated based on the creatinine levels on admission
sing the simplified Modified Diet in Renal Disease
MDRD) formula (19). In an effort to examine the influ-
nce of dynamic changes in serum creatinine in the setting
f HF, each subject’s record was reviewed for serial serum
reatinine levels following presentation. An increase or
ecrease in creatinine was defined by any increase or
ecrease 0.3 mg/dl during admission.
tatistical analyses. Data are presented as median values
ith intraquartile range (IQR) for non-normally distributed
ariables and mean  standard deviation (SD) for all other
ontinuous variables. For NT-proBNP analyses, HF pa-
ients were dichotomized to above/below median NT-
roBNP levels. For analyses of renal function, patients were
ichotomized to GFR above or below 60 ml/min/1.73 m2,
oth the mean value for the population as well as reflecting
Abbreviations and Acronyms
BNP  brain natriuretic peptide
GFR  glomerular filtration rate
HF  heart failure
ICON  International Collaborative on
NT-proBNP
MDRD  Modified Diet in Renal Disease
NT-proBNP  amino-terminal pro-brain natriuretic
peptidecut-off value based on the standards of the National tidney Foundation (2,4,20). To investigate dynamic aspects
n renal function, we also divided our population according
o previously published criteria for the cardiorenal syndrome
21), namely, an increase in creatinine level during hospital
dmission 0.3 mg/dl. We also identified subjects with a
ecrease in creatinine level 0.3 mg/dl and those with a
table creatinine level.
Differences in baseline variables between survivors and
onsurvivors were analyzed using the Wilcoxon rank sum
est for continuous variables and Pearson chi-square testing
or categoric variables. Survival curves were computed with
he Kaplan-Meier curves, and differences between the
urves were evaluated with the log-rank statistic.
Univariate screening of baseline variables was used to
dentify candidate independent predictors of 60-day mor-
ality. Multivariable analysis with forward stepwise logistic
egression, including all candidate variables with p values
0.10 or of predetermined clinical interest, was performed
o identify independent predictors of 60-day mortality.
oodness of fit was evaluated with the Hosmer-
emeshow test. Other than an interaction between NT-
roBNP  median value and GFR 60 ml/min/1.73 m2
p  0.001), all other independent variables were evalu-
ted in pairs for first-order interactions, and none were
ound. Results are presented as odds ratios (OR) with
5% confidence intervals (CI).
ESULTS
f the 1,256 overall patients included in the ICON study,
20 (57%) were diagnosed with acute HF at presentation.
mong these 720 subjects with acute HF, the median
T-proBNP concentration was 4,647 pg/ml. The mean
erum creatinine was 1.3  0.68 mg/dl, with a correspond-
ng mean GFR of 60.5  26.0 ml/min/1.73 m2; accord-
ngly, 373 subjects (51.8%) had a GFR below 60 ml/min/
.73 m2. Comparisons of various characteristics germane to
he present analysis, as a function of study site, are demon-
trated in Table 1.
Amino-terminal pro-BNP was negatively related to GFR
r  0.34; p  0.001). Subjects with a GFR 60 ml/min/
.73 m2 (n  373) had higher median NT-proBNP
oncentrations than those (n  347) with GFR 60
l/min/1.73 m2 (7,214 pg/ml [IQR  2,757 to 16,160] vs.
,054 pg/ml [IQR  1,345 to 7,620 pg/ml]; p  0.001 for
ifference).
ortality analysis. Eighty-nine patients (12.4%) with
cute HF died within 60 days. Patient characteristics as a
unction of survival are shown in Table 2. Subjects dying
ithin 60 days were more likely to be older, to have a history
f coronary artery disease and left bundle branch block on
lectrocardiogram, and to present with fever or the absence
f paroxysmal nocturnal dyspnea than survivors. In addition,
ecedents were also more likely to have worse renal func-
ion, to be anemic, to have higher cardiac troponin T
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October 17, 2006:1621–7 NT-proBNP, Renal Function, and Outcome in HFcTnT) concentrations, and to have more elevated NT-
roBNP concentrations.
In multivariate analyses that included age, prior HF, prior
yocardial infarction, severity of dyspnea (New York Heart
able 1. Comparisons of Various Characteristics as a Function o
Characteristic Maastricht (n  36
T-proBNP, pg/ml (median, interquartile range) 6,842 (2,888–12,626
erum creatinine, mg/dl (mean  SD) 1.4  0.8
lomerular filtration rate (mg/min/1.73m2),
mean  SD
55  24
erum creatinine patterns following admission
Rise 0.3 mg/dl 45%
Fall 0.3 mg/dl 7.1%
0-day mortality 15.6%
/A  not available; NT-proBNP  amino-terminal pro-brain natriuretic peptide.
able 2. Comparisons of Patients With Acute Heart Failure Bas
Characteristic Alive at D
ge, yrs (mean  SD) 7
ale gender
lack race
edical history
Hypertension
Coronary artery disease
Prior acute myocardial infarction
Prior heart failure
Prior obstructive airways disease
Smoking (past or present)
ymptoms/signs
Paroxysmal nocturnal dyspnea
Orthopnea
Lower extremity edema
Chest pain
Cough
Fever
Increased sputum
NYHA functional class 4
hysical examination
Pulse rate (mean  SD) 9
Jugular venous distension
S3 gallop
Lower extremity edema
Rales
Wheezing
lectrocardiographic findings
Sinus rhythm
Atrial fib/flutter
Left ventricular hypertrophy
Left bundle branch block
hest X-ray findings
Interstitial edema
Infiltrate
Pleural effusion
Cephalization of vessels
Cardiomegaly
aboratory findings
Creatinine, mg/dl (median, interquartile range) 1.12
GFR, ml/min/1.73m2 (median, interquartile range) 60.7
Troponin T 0.01 ng/ml
Hemoglobin, g/dl (mean  SD) 1
NT-proBNP, pg/ml (median, interquartile range) 4,077FR  glomerular filtration rate; NT-proBNP  amino-terminal pro-brain natriuretic pessociation functional classification), hemoglobin levels,
TnT results, GFR60 ml/min/1.73 m2, and NT-proBNP
evel above the median value, both GFR 60 ml/min/
.73 m2 (OR 2.03; 95% CI 1.18 to 3.49) and NT-proBNP
Study Site
Boston (n  209) Barcelona (n  80) Christchurch (n  66)
4,054 (1,674–10,027) 3,538 (2,115–10,017) 854 (441–1,951)
1.3  0.5 1.1  0.7 1.0  0.2
58  25 77  31 78  22
37% N/A 21%
4.8% N/A 18.2%
8.1% 6.3% 15.2%
the 60-Day Survival
0 (n  606) Deceased by Day 60 (n  84) p Value
11.7 78.5  10.6 0.002
% 52.4% 0.833
% 0% 0.237
% 51.2% 0.056
% 65.5% 0.011
% 42.2% 0.112
% 54.8% 0.593
% 26.2% 0.561
% 52.4% 0.985
% 19.0% 0.009
% 48.4% 0.635
% 45.2% 0.823
% 32.5% 0.861
% 27.4% 0.361
% 10.7% 0.009
% 16.7% 0.713
% 50.0% 0.319
25.8 95.5  26.0 0.381
% 56.0% 0.222
% 8.3% 0.639
% 52.4% 0.501
% 67.9% 0.882
% 10.7% 0.151
% 64.3% 0.408
% 32.1% 0.671
% 8.3% 0.499
% 25.0% 0.02
% 29.8% 0.161
% 16.7% 0.196
% 22.6% 0.440
% 35.7% 0.235
% 39.3% 0.680
–1.50) 1.41 (1.02–2.10) 0.001
0–79.22) 43.9 (30.92–64.03) 0.001
% 77.3% 0.001
2.06 12.0  1.97 0.003
0–9,989) 9,448 (3,805–22,179) 0.001f the
5)
)ed on
ay 6
4.4 
51.2
2.5
62.0
50.7
33.3
51.7
29.3
51.9
33.2
51.6
46.5
33.5
32.8
4.1
18.3
44.2
2.8 
48.8
6.9
56.3
68.7
16.9
59.6
34.5
10.7
15.0
37.6
11.7
26.6
29.4
37.0
(0.87
(42.9
47.5
2.7 
(1,74ptide; NYHA  New York Heart Association.
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NT-proBNP, Renal Function, and Outcome in HF October 17, 2006:1621–7oncentrations above the median (OR 2.67; 95% CI 1.58 to
.51) strongly predicted 60-day mortality in an independent
ashion (Table 3). Notably, in a secondary analysis, the
ombination of both GFR 60 ml/min/1.73 m2 and
T-proBNP level above the median was an even stronger
able 3. Multivariate Analysis Using Individual and Combined
easures of Cardiac and Renal Insufficiency for the Prediction
f Death by 60 Days Following Presentation With Acute Heart
ailure (HF)
Predictor Odds Ratio 95% CI p Value
Individual Measures
ge 1.02 0.99–1.05 0.08
rior HF 0.78 0.48–1.27 0.31
rior myocardial infarction 1.36 0.84–2.22 0.22
YHA functional class 1.26 0.86–1.86 0.24
emoglobin 0.94 0.88–1.01 0.07
roponin T 0.01 ng/ml 1.52 0.89–2.01 0.08
FR 60 ml/min/1.73 m2 2.03 1.18–3.49 0.001
T-proBNP 4,647 pg/ml 2.67 1.58–4.51 0.001
Combined Measures
ge 1.02 0.99–1.05 0.06
rior HF 0.78 0.48–1.27 0.31
rior myocardial infarction 1.37 0.84–2.24 0.20
YHA functional class 1.24 0.84–1.83 0.28
emoglobin 0.94 0.88–1.01 0.07
roponin T 0.01 ng/ml 1.32 0.83–2.05 0.10
FR 60 ml/min/1.73 m2 and
NT-proBNP 4,647 pg/ml
3.46 2.13–5.63 0.001
I  confidence interval; other abbreviations as in Table 2.igure 1. Survival curves of heart failure subjects in ICON (International Collab
nd amino-terminal pro-brain natruiuretic peptide (NT-proBNP) concentrationredictor of mortality than either measure alone (OR 3.46;
5% CI 2.13 to 5.63) (Table 3).
Kaplan-Meier survival curves depicting mortality rates as
function of NT-proBNP concentration and GFR (Fig. 1)
emonstrate that the majority of fatal events in the first 60
ays from presentation occurred in subjects with an NT-
roBNP level above the median plus a GFR 60 ml/min/
.73 m2, with low rates of mortality (and no statistical
ifference) in the other categories, including HF with a
FR 60 ml/min/1.732 but with an NT-proBNP below
he median.
enal function, NT-proBNP, and 60-day survival. In an
ffort to better understand the relationship between renal
unction and HF outcomes, we examined the relationship
etween dynamic changes in serum creatinine in the setting
f acute HF, and outcomes (5). This group of subjects (n 
27) with available data was similar to the group as a whole
n terms of baseline demographics, including a similar
T-proBNP median of 4,694 pg/ml, and was dichoto-
ized with respect to NT-proBNP concentrations above or
elow the median and analyzed as a function of serum
reatinine changes. In recognition of previous definitions of
ardiorenal syndrome (4,5,21), the outcomes of those sub-
ects with an in-hospital rise of serum creatinine0.3 mg/dl
ere compared with those without a rise in creatinine. In
ddition, we examined the outcomes of subjects whose
reatinine fell by 0.3 mg/dl during their hospitalization.
his left 3 diagnostic categories within NT-proBNPorative on NT-proBNP) as a function of glomerular filtration rate (GFR)
on admission (log-rank p  0.001).
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October 17, 2006:1621–7 NT-proBNP, Renal Function, and Outcome in HFroups, those with: 1) an increase in serum creatinine 0.3
g/dl; 2) those with change in serum creatinine0.3 mg/dl
uring hospitalization; and 3) those with a decrease in
erum creatinine 0.3 mg/dl following presentation.
The outcomes of subjects as a function of NT-proBNP
oncentration and dynamic changes in serum creatinine are
hown in Figure 2. Among the HF patients with an
T-proBNP level above the median, those with a rise in
erum creatinine (n  173) had the worst overall 60-day
rognosis, those subjects with high NT-proBNP but with
o change in creatinine (n  110) had intermediate out-
omes, and those with a fall in serum creatinine0.3 mg/dl
n  28) had the most benign outcomes (but which were
onetheless worse than those with an NT-proBNP below
he median). In each case, all 3 groups had significantly
orse outcomes (p  0.001) than those with NT-proBNP
oncentrations below the median.
To get a better understanding of the relationship between
FR and dynamic changes in renal function, we examined
he relationship between presenting GFR and the preva-
ence of subsequent dynamic changes in renal function. We
ound that among those patients with a rise in serum
reatinine0.3 mg/dl during treatment for acute HF, more
ad a presenting GFR 60 ml/min/1.73 m2 (44.8% vs.
2.9%; p  0.01), and were more likely to have the adverse
ombination of a low GFR together with an elevated
T-proBNP compared with those with a GFR 60
l/min/1.73 m2 (29.1% vs. 13.0%; p  0.001).igure 2. Survival curves of heart failure subjects in ICON as a function of NT-p
ollowing presentation (log-rank p  0.001). Abbreviations as in Figure 1.Notably, in those patients with NT-proBNP levels below
he median value of 4,694 pg/ml, we found no graded
elationship between dynamic changes in creatinine and
ates of mortality.
ISCUSSION
he complex interaction between heart and kidneys remains
poorly understood area and one of great focus in modern
edicine. Using data from the ICON study, we demon-
trated the dynamic interaction between HF, renal function,
nd outcomes, emphasizing the value of the addition of an
bjective measure of HF severity (NT-proBNP) to an
bjective measurement of renal function (GFR or serum
reatinine) to better stratify risk in acute HF.
Besides sharing strong commonality with respect to risk
actors for their development, cardiac and renal impairment
re strongly connected on a neurohormonal basis via the
enin-angiotensin-aldosterone system and its antagonists
BNP and nitric oxide), the sympathetic nervous system, as
ell as inflammatory pathways (22). Furthermore, in the
etting of acute HF, the dynamic relationship between the
eart and kidneys may be accentuated: cardiac output is
educed, which may be counteracted by systemic and other
esponses such as a decrease in renal blood flow to retain
irculating fluid and restore cardiac output (5,23). In addi-
ion, the uremic milieu itself may further affect cardiac
ontractility, with promotion of myocyte fibrosis and death
24,25). It is thus not at all surprising that measures ofroBNP concentration on admission and dynamic changes in renal function
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NT-proBNP, Renal Function, and Outcome in HF October 17, 2006:1621–7ardiac insufficiency, such as natriuretic peptides, are
trongly influenced by the presence and severity of renal
nsufficiency.
This combination of acute cardiac and renal insufficiency—
ften termed “cardiorenal syndrome” (4,5)—is a marker of
articularly high risk for adverse outcome in the setting of
cute HF (26).
In this analysis of NT-proBNP and renal function in
ubjects with acute HF, we report several important findings
ith potentially useful clinical implications. Consistent with
ll other studies (9,27–31), we show NT-proBNP as a
owerful predictor of mortality in acute HF, remaining so in
he presence of normal or impaired renal function. How-
ver, in none of the previously published studies (9,27–31)
as GFR taken into account in the multivariate analyses.
otably, although NT-proBNP and GFR were each sig-
ificantly related to mortality, the novel approach of com-
ining the 2 measures led to our finding that the combina-
ion was a superior tool for identifying patients with HF at
ighest risk for short-term death, while also demonstrating
hat, in our study, many HF subjects with moderate or
orse renal insufficiency but lower NT-proBNP concentra-
ions had 60-day outcomes comparable to those without
ignificant renal insufficiency. Interestingly, as depicted in
igure 1, patients with an elevated NT-proBNP in the
bsence of renal impairment had a prognosis comparable
ith patients with renal impairment. In addition, while
nalyzing the concept of dynamic changes in “cardiorenal”
nsufficiency, we demonstrated the utility of NT-proBNP to
tratify the subjects to a wide range of risks within various
ategories of renal function. Importantly, though a rise in
reatinine indeed identified subjects at higher risk for
ortality following presentation (the classic definition of
he cardiorenal syndrome), this risk was only present in
hose with elevated NT-proBNP concentrations. Those
ubjects with creatinine rise during admission but without a
arkedly elevated NT-proBNP level demonstrated a rela-
ively low 60-day mortality rate similar to subjects with a
ow NT-proBNP level, regardless of their evolution in
reatinine. Our data suggest that defining the cardiorenal
yndrome simply as the development of worsened renal
unction in a patient with HF may require reconsideration.
ndeed, the heterogeneity of cardiorenal insufficiency was
ecently emphasized by Forman et al. (32), who demon-
trated that HF patients with deterioration in renal function
re not simply those with the poorest ventricular function,
ut included patients with preserved systolic function, fewer
omplaints of low output (such as fatigue), as well as high
lood pressure.
Although most prior analyses of cardiorenal interaction
ave focused on those subjects with HF and a rise in serum
reatinine, the outcomes of those subjects with an improve-
ent in renal function (accounting for more than 11% of
he present study population) consequent to treatment for
F remains less well described. We also described the
roup of patients with elevated NT-proBNP in whom serum creatinine fell following presentation. In the subjects
ith markedly elevated NT-proBNP, a falling creatinine
as associated with a statistically significantly lower risk of
eath compared with those with an elevated NT-proBNP
nd either a rise or no change in renal measurements.
otably, however, the outcomes of subjects in ICON with
high NT-proBNP and improvement in serum creatinine
ere still worse than those with low NT-proBNP.
Although it is generally accepted that renal impairment
orrelates with poor outcome in patients with HF (1–3),
here is still some debate whether a rise in serum creatinine
s the best expression of renal impairment in HF, or if
elative increase in serum creatinine or a high serum
reatinine on admission (32–34) better reflect “cardiorenal”
isk. Although our data suggest that both GFR or dynamic
hanges in renal function offer relatively comparable prog-
ostic data, in the setting of a high presenting NT-proBNP,
GFR 60 ml/min/1.73 m2 on admission provides these
rognostic data right at presentation, rather than requiring
erial measurements of creatinine.
tudy limitations. Limitations of our study include, first,
he fact that GFR estimation was performed using the
DRD equation rather than directly measuring renal
unction. The MDRD equation is accepted to be a generally
ccurate measure of renal function and in the present study
rovided robust results regarding prognosis. Second, only a
mall number of African Americans were included in this
rial, and our findings should therefore carefully be extrap-
lated to this population. Third, as in all studies discussing
he cardiorenal syndrome, the measurement of serum creat-
nine for assessment of dynamic changes in renal function was
erformed at variable time intervals in our study. Fourth,
ecause the number of creatinine observations would typically
e expected to be greater in sicker patients, the risk for
onfounding/bias is increased owing to the potential for
ssues pertaining to ascertainment of these sicker patients.
onetheless, our results are quite consistent with those
reviously described and make intuitive sense as well. Last,
t is important to realize that our study was an observational
tudy and not an interventional study, and although all
atients were treated according to guidelines known at that
ime point it may be that our results would be slightly
ifferent if the results from later trials (e.g., the CARE-HF
Cardiac Resynchronization Heart Failure] [35]) would be
aken into account.
onclusions. The combined use of objective parameters of
ardiac (NT-proBNP) and renal (GFR) function allowed
dentification of those HF patients at highest risk for
hort-term death and argues that elevations of NT-proBNP
n the setting of renal insufficiency are not, in fact, spurious.
oreover, analyses of the rates of mortality based on
ynamic changes in renal function suggest a graded risk for
eath among those with highest concentrations of NT-
roBNP. This latter finding lends support to the consider-
tion that therapies aimed specifically at the cardiorenal
yndrome (36), may improve survival in these patients (5).
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October 17, 2006:1621–7 NT-proBNP, Renal Function, and Outcome in HFinally, our data may support a reconsideration of the
efinition of cardiorenal syndrome to include a natriuretic
eptide standard rather than the clinical diagnosis of HF to
escribe the cardiovascular element to this complex syn-
rome of combined cardiac and renal insufficiencies.
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